Description
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered to resist rapid enzymatic degradation while retaining the core receptor-binding sequence of native GHRH.
In laboratory research, the compound is used to study stimulation of the growth hormone releasing hormone receptor (GHRHR) on the pituitary somatotroph, providing a model for examining pulsatile growth hormone release independent of the extended half-life conferred by Drug Affinity Complex (DAC) technology.
Because it lacks the DAC modification, CJC-1295 without DAC produces a shorter, sharper signaling window than its DAC-conjugated counterpart, making it a useful comparative tool for researchers studying dose-response kinetics and receptor desensitization in the GH/IGF-1 axis.
It is frequently paired with ghrelin-mimetic secretagogues in combination research protocols to examine synergistic activation of the growth hormone signaling pathway through complementary receptor mechanisms.
As a research reagent, CJC-1295 without DAC supports investigations into pituitary function, peptide stability engineering, and the broader regulatory architecture of the somatotropic axis.
Reviews
There are no reviews yet.